TY  - JOUR
T1  - Antibody Development in Swine Against a Hog Cholera Lethal Strain
AU - , Maria Antonia Coba Ayala AU - , E. Pablo Correa Giron AU - , Atalo Martinez Lara AU - , Susana Mendoza Elvira AU - , Abel Ciprian Carrasco AU - , Oscar Torre AU - , Edgar Aguilera Ceron 
JO  - Journal of Animal and Veterinary Advances
VL  - 7
IS  - 1
SP  - 94
EP  - 99
PY  - 2008
DA  - 2001/08/19
SN  - 1680-5593
DO  - javaa.2008.94.99
UR  - https://makhillpublications.co/view-article.php?doi=javaa.2008.94.99
KW  - Hog Cholera
KW  -classical swine fever
KW  -pav-250 vaccinial strain
KW  -ald pathogenic strain
KW  -immunization
AB  - Pathogenic Hog Cholera (HC) Virus (V) generally kills inoculated pigs before the development of detectable antibodies, making difficult to produce an immune sera against the ALD exposition pathogenic live-virus. With this last purpose a procedure was evaluated by inoculating 2 HCV seronegative pigs, initially with highly diluted dosages of challenge HCV (ALD strain/with an initial titer of 10<SUP>4.99</SUP>CCID<SUB>50</SUB>/mL) and then progressively with more concentrated dosages (from 10<SUP>-11</SUP> to 10<SUP>-1</SUP>). This allowed to produce the disease with a long incubation period. The 2 pigs presented fever and HC clinical signs and survived 30 and 38 days after inoculation, respectively. In a second phase, in an attempt to produce a HC immune serum, 5 groups of 4 susceptible pigs were immunized as follows Group (G) I, Negative Control; G II vaccinated with the PAV-250 HC vaccine; G III, inoculated with 1 mL ALD-HCV (10<SUP>4.0</SUP>/mL); G IV, vaccinated and challenged with ALD-HCV; G V, vaccinated twice andALD-HCV challenged. G I was negative. HC-antibody titres of  >=1:10 were detected at 14 Post Challenge (PC) days in Control Groups II, IV and V and at 15 PC. days in Group III. HC antibodies developed in G III because pigs had enough time for antibody production after being inoculated. The utilized challenge dilution (10<SUP>4.0</SUP> /mL) was satisfactory for obtaining immune sera against the pathogenic live HCV-ALD, in G III; Control groups II, IV and V also produced satisfactory immune sera.
ER  -